

DAFTAR PUSTAKA

- Afiatin, Suhaimi, N. and Puspitasari, M. (2020) *13 th ANNUAL REPORT OF INDONESIAN RENAL REGISTRY 2020*. Available at: <https://indonesianrenalregistry.org/media/ANNUAL%20REPORT%20IRR%202020.pdf> (Accessed: 17 July 2025).
- Akbari, M. and Hassan-Zadeh, V. (2018) 'IL-6 signalling pathways and the development of type 2 diabetes', *Inflammopharmacology*, 26(3), pp. 685–698. doi: 10.1007/s10787-018-0458-0.
- Astarini, D., Aphridasari, J. and Setijadi, A. R. (2024) 'The Role of Omega-3 on the IL-6 Levels, Malondialdehyde, and Clinical Improvement in Adults with Community-Acquired Pneumonia', *Jurnal Respirologi Indonesia*, 44(1), pp. 28–35. doi: 10.36497/jri.v44i1.402.
- Banaszak, M. *et al.* (2024) 'Role of Omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) as modulatory and anti-inflammatory agents in noncommunicable diet-related diseases – Reports from the last 10 years', *Clinical Nutrition ESPEN*, 63, pp. 240–258. doi: 10.1016/j.clnesp.2024.06.053.
- Barreto, D. V. *et al.* (2010) 'Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease', *Kidney International*, 77(6), pp. 550–556. doi: 10.1038/ki.2009.503.
- Basil, M. C. and Levy, B. D. (2016) 'Specialized pro-resolving mediators: endogenous regulators of infection and inflammation', *Nature Reviews Immunology*, 16(1), pp. 51–67. doi: 10.1038/nri.2015.4.
- Batra, G. *et al.* (2021) 'Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome', *JAMA Cardiology*, 6(12), p. 1440. doi: 10.1001/jamacardio.2021.3079.
- Bhide, A., Shah, P. S. and Acharya, G. (2018) 'A simplified guide to randomized controlled trials', *Acta Obstetrica et Gynecologica Scandinavica*, 97(4), pp. 380–387. doi: 10.1111/aogs.13309.
- Brookhyser, J. (2006) 'Omega 3 Fatty Acids', *Journal of Renal Nutrition*, 16(3), pp. e7–e10. doi: 10.1053/j.jrn.2006.04.003.
- Calder, P. C. (2010) 'Omega-3 Fatty Acids and Inflammatory Processes', *Nutrients*, 2(3), pp. 355–374. doi: 10.3390/nu2030355.
- Calder, P. C. (2012) 'Mechanisms of Action of (n-3) Fatty Acids', *The Journal of Nutrition*, 142(3), pp. 592S-599S. doi: 10.3945/jn.111.155259.

- Calder, P. C. (2013) ‘Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?’, *British Journal of Clinical Pharmacology*, 75(3), pp. 645–662. doi: 10.1111/j.1365-2125.2012.04374.x.
- Chen, T. K., Knicely, D. H. and Grams, M. E. (2019) ‘Chronic Kidney Disease Diagnosis and Management’, *JAMA*, 322(13), p. 1294. doi: 10.1001/jama.2019.14745.
- Das, U. N. (2013) ‘n-3 fatty acids, γ -linolenic acid, and antioxidants in sepsis’, *Critical Care*, 17(2), p. 312. doi: 10.1186/cc12574.
- Depner, T. A. (2017) ‘Uremic Toxicity’, in *Handbook of Dialysis Therapy*. Elsevier, pp. 241-263.e1. doi: 10.1016/B978-0-323-39154-2.00018-7.
- Ferrucci, L. *et al.* (2005) ‘The origins of age-related proinflammatory state’, *Blood*, 105(6), pp. 2294–2299. doi: 10.1182/blood-2004-07-2599.
- Ghanei, E. *et al.* (2012) *Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial*, *Iranian Red Crescent Medical Journal Iran Red Crescent Med J*. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3482323/pdf/ircmj-14-515.pdf> (Accessed: 12 December 2024).
- Giuliani, N. *et al.* (2001) ‘Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes’, *Experimental Gerontology*, 36(3), pp. 547–557. doi: 10.1016/S0531-5565(00)00220-5.
- Goicoechea, M. *et al.* (2012) ‘Intraindividual Interleukin-6 Variations on the Cardiovascular Prognosis of Patients with Chronic Renal Disease’, *Renal Failure*, 34(8), pp. 1002–1009. doi: 10.3109/0886022X.2012.696469.
- Gong, Y. *et al.* (2019) ‘Effects of blood sample handling procedures on measurable interleukin 6 in plasma and serum’, *Journal of Clinical Laboratory Analysis*, 33(7). doi: 10.1002/jcla.22924.
- Grebenciucova, E. and VanHaerents, S. (2023) ‘Interleukin 6: at the interface of human health and disease’, *Frontiers in Immunology*, 14. doi: 10.3389/fimmu.2023.1255533.
- Guo, Y. *et al.* (2023) ‘n -3 PUFA can reduce IL-6 and TNF levels in patients with cancer’, *British Journal of Nutrition*, 129(1), pp. 54–65. doi: 10.1017/S0007114522000575.
- Hariton, E. and Locascio, J. J. (2018) ‘Randomised controlled trials – the gold standard for effectiveness research’, *BJOG: An International Journal of*

Obstetrics & Gynaecology, 125(13), pp. 1716–1716. doi: 10.1111/1471-0528.15199.

- Himmelfarb, J. *et al.* (2007) ‘Gamma-Tocopherol and Docosahexaenoic Acid Decrease Inflammation in Dialysis Patients’, *Journal of Renal Nutrition*, 17(5), pp. 296–304. doi: 10.1053/j.jrn.2007.05.011.
- Hu, C. *et al.* (2018) ‘Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue’, *Therapeutic Apheresis and Dialysis*, 22(2), pp. 124–132. doi: 10.1111/1744-9987.12611.
- Hu, J., Liu, Z. and Zhang, H. (2017) ‘Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis’, *Clinics*, 72(1), pp. 58–64. doi: 10.6061/clinics/2017(01)10.
- Hustrini, N. M., Susalit, E. and Rotmans, Joris I (2022) ‘Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018’, *J Glob Health*, 12. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9559178/pdf/jogh-12-04074.pdf> (Accessed: 11 December 2024).
- Itariu, B. K. *et al.* (2012) ‘Long-chain n–3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial’, *The American Journal of Clinical Nutrition*, 96(5), pp. 1137–1149. doi: 10.3945/ajcn.112.037432.
- Jones, B. E., Maerz, M. D. and Buckner, J. H. (2018) ‘IL-6: a cytokine at the crossroads of autoimmunity’, *Current Opinion in Immunology*, 55, pp. 9–14. doi: 10.1016/j.coi.2018.09.002.
- Kalantar-Zadeh, K. *et al.* (2003) ‘Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences’, *American Journal of Kidney Diseases*, 42(5), pp. 864–881. doi: 10.1016/j.ajkd.2003.07.016.
- KDIGO (2013) *KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. Available at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf (Accessed: 24 November 2024).
- Kemntrian Kesehatan RI (2019) *Laporan Riskesdas 2018 Nasional*. Available at: <https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan%20Riskesdas%202018%20Nasional.pdf> (Accessed: 24 November 2024).
- Khosla, S. *et al.* (2002) ‘Effect of Estrogen *versus* Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men’, *The*

Journal of Clinical Endocrinology & Metabolism, 87(4), pp. 1550–1554.
doi: 10.1210/jcem.87.4.8397.

- Kooshki, A. *et al.* (2011) ‘Effects of Marine Omega-3 Fatty Acids on Serum Systemic and Vascular Inflammation Markers and Oxidative Stress in Hemodialysis Patients’, *Annals of Nutrition and Metabolism*, 58(3), pp. 197–202. doi: 10.1159/000329727.
- Kovesdy, C. P. (2022) ‘Epidemiology of chronic kidney disease: an update 2022’, *Kidney International Supplements*, 12(1), pp. 7–11. doi: 10.1016/j.kisu.2021.11.003.
- Kreiner, F. F. *et al.* (2022) ‘Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives’, *Expert Review of Clinical Immunology*, 18(4), pp. 377–389. doi: 10.1080/1744666X.2022.2045952.
- Kremer, J. M. *et al.* (1990) *DIETARY FISH OIL AND OLIVE OIL SUPPLEMENTATION IN PATIENTS WITH RHEUMATOID ARTHRITIS Clinical and Immunologic Effects*. Available at: <https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780330607?sid=nlm%3Apubmed> (Accessed: 24 July 2025).
- Lahiji, A. P. *et al.* (2018) ‘Omega-3 Supplementation Improves Pruritus in Continuous Ambulatory Peritoneal Dialysis Patients’, *Journal of Research in Pharmacy Practice*, 7(4), pp. 195–199. doi: 10.4103/jrpp.JRPP_18_64.
- Lambert, C. P., Sullivan, D. H. and Evans, W. J. (2003) ‘Effects of Testosterone Replacement and/or Resistance Training on Interleukin-6, Tumor Necrosis Factor Alpha, and Leptin in Elderly Men Ingesting Megestrol Acetate: A Randomized Controlled Trial’, *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, 58(2), pp. M165–M170. doi: 10.1093/gerona/58.2.M165.
- Lange, K. W. *et al.* (2019) ‘Are there serious adverse effects of omega-3 polyunsaturated fatty acid supplements?’, *Journal of Food Bioactives*, pp. 1–6. doi: 10.31665/JFB.2019.7192.
- Lestari, S. (2025) *Pengaruh Pemberian 500 Miligram Asam Askorbat Intravena Dua Kali Seminggu Selama 12 Minggu Terhadap Penurunan Kadar Interleukin-6 dan HS-CRP Pada Pasien Penyakit Ginjal Tahap Akhir Yang Menjalani Hemodialisis Rutin*. Tesis tidak dipublikasikan. Universitas Gadjah Mada.
- Li, K. *et al.* (2014) ‘Effect of Marine-Derived n-3 Polyunsaturated Fatty Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α : A Meta-Analysis’, *PLoS ONE*, 9(2), p. e88103. doi: 10.1371/journal.pone.0088103.

- Lin, Y.-L. *et al.* (2022) ‘Omega-3 Fatty Acids Improve Chronic Kidney Disease—Associated Pruritus and Inflammation’, *Medicina*, 58(6), p. 796. doi: 10.3390/medicina58060796.
- Ma, Y. *et al.* (2016) ‘The effects of omega-3 polyunsaturated fatty acids and genetic variants on methylation levels of the interleukin-6 gene promoter’, *Molecular Nutrition & Food Research*, 60(2), pp. 410–419. doi: 10.1002/mnfr.201500436.
- Maggio, M. *et al.* (2006) ‘Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway’, *The Journals of Gerontology: Series A*, 61(6), pp. 575–584. doi: 10.1093/gerona/61.6.575.
- Malkin, C. J. *et al.* (2004) ‘The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men’, *The Journal of Clinical Endocrinology & Metabolism*, 89(7), pp. 3313–3318. doi: 10.1210/jc.2003-031069.
- Moertl, D. *et al.* (2011) ‘Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin’, *American Heart Journal*, 161(5), pp. 915.e1-915.e9. doi: 10.1016/j.ahj.2011.02.011.
- Moreira, A. C. *et al.* (2007) ‘Effect of a Sardine Supplement on C-Reactive Protein in Patients Receiving Hemodialysis’, *Journal of Renal Nutrition*, 17(3), pp. 205–213. doi: 10.1053/j.jrn.2007.02.005.
- Multum, C. (2023) *Omega-3 polyunsaturated fatty acids*, *Drugs.com*. Available at: <https://www.drugs.com/mtm/omega-3-polyunsaturated-fatty-acids.html> (Accessed: 13 December 2024).
- Ong, K. L. *et al.* (2023) ‘Association of omega 3 polyunsaturated fatty acids with incident chronic kidney disease: pooled analysis of 19 cohorts’, *BMJ*, p. e072909. doi: 10.1136/bmj-2022-072909.
- Panahi, Y. *et al.* (2016) ‘Therapeutic Effects of Omega-3 Fatty Acids on Chronic Kidney Disease-Associated Pruritus: a Literature Review’, *Advanced Pharmaceutical Bulletin*, 6(4), pp. 509–514. doi: 10.15171/apb.2016.064.
- Qu, D. *et al.* (2014) ‘IL-6 in diabetes and cardiovascular complications’, *British Journal of Pharmacology*, 171(15), pp. 3595–3603. doi: 10.1111/bph.12713.
- Reddenna, L. *et al.* (2014) ‘Dialysis Treatment: A Comprehensive Description’, 3(1), pp. 1–13. Available at: <https://ijpras.com/storage/models/article/H1PU7jpHW1WMtxyZEGvKW9>

09Wqn54JvD2ouCW01tVZ0KxtbN3B9Z2RR6gVK3/dialysis-treatment-a-comprehensive-description.pdf (Accessed: 17 August 2024).

- Ridker, P. M. *et al.* (2018) ‘Inhibition of Interleukin-1 β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease’, *Journal of the American College of Cardiology*, 71(21), pp. 2405–2414. doi: 10.1016/j.jacc.2018.03.490.
- Rosalinda, J. (2023) *Faktor-Faktor yang Mempengaruhi Tingkat Kepatuhan Pengobatan Pasien Diabetes Melitus Tipe 2 di Puskesmas Kotagede II Yogyakarta, Health Information : Jurnal Penelitian*. Available at: <https://myjurnal.poltekkes-kdi.ac.id/index.php/hijp/article/view/1323> (Accessed: 24 July 2025).
- Rosner, M. H. *et al.* (2021) ‘Classification of Uremic Toxins and Their Role in Kidney Failure’, *Clinical Journal of the American Society of Nephrology*, 16(12), pp. 1918–1928. doi: 10.2215/CJN.02660221.
- Schunk, S. J. *et al.* (2021) ‘Interleukin-1 α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease’, *Circulation*, 144(11), pp. 893–908. doi: 10.1161/CIRCULATIONAHA.121.053547.
- Shahidi, F. and Ambigaipalan, P. (2018) ‘Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits’, *Annual Review of Food Science and Technology*, 9(1), pp. 345–381. doi: 10.1146/annurev-food-111317-095850.
- Shayanpour, S. *et al.* (2017) ‘The effect of the omega-3 supplement on uremic pruritus in hemodialysis patients; a double-blind randomized controlled clinical trial’, *Journal of Nephropathology*, 8(2), pp. 13–13. doi: 10.15171/jnp.2019.13.
- Stevens, P. E. *et al.* (2024) ‘KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease’, *Kidney International*, 105(4), pp. S117–S314. doi: 10.1016/j.kint.2023.10.018.
- Stopic, B. *et al.* (2022) ‘Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease’, *Dose-Response*, 20(3). doi: 10.1177/15593258221127568.
- Su, H., Lei, C.-T. and Zhang, C. (2017) ‘Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update’, *Frontiers in Immunology*, 8. doi: 10.3389/fimmu.2017.00405.
- Susilo, H. *et al.* (2022) ‘The Role of Plasma Interleukin-6 Levels on Atherosclerotic Cardiovascular Disease and Cardiovascular Mortality Risk Scores in

Javanese Patients with Chronic Kidney Disease', *Journal of Personalized Medicine*, 12(7), p. 1122. doi: 10.3390/jpm12071122.

- Tanaka, T., Narazaki, M. and Kishimoto, T. (2014) 'IL-6 in Inflammation, Immunity, and Disease', *Cold Spring Harbor Perspectives in Biology*, 6(10), pp. a016295–a016295. doi: 10.1101/cshperspect.a016295.
- Tando, W. (2018) *Pengaruh Pemberian Asam Lemak Omega-3 Terhadap Penanda Inflamasi TNF- α Dan CRP Pada Pasien Yang Menjalani Hemodialisis Reguler*. Makassar. Available at: http://repository.unhas.ac.id/4024/2/18_C117215106%28FILEminimizer%29%20...%20ok%201-2.pdf (Accessed: 29 January 2025).
- Trebble, T. *et al.* (2003) 'Inhibition of tumour necrosis factor- α and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation', *British Journal of Nutrition*, 90(2), pp. 405–412. doi: 10.1079/BJN2003892.
- Valle Flores, J. A. *et al.* (2020) 'Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis', *Applied Physiology, Nutrition, and Metabolism*, 45(8), pp. 805–811. doi: 10.1139/apnm-2019-0729.
- Vanholder, R. (2023) *Uremic Toxins, UpToDate*. Available at: <https://www.uptodate.com/contents/uremic-toxins> (Accessed: 18 August 2024).
- WebMD (2024) *OMEGA-3 - Uses, Side Effects, and More, WebMD.com*. Available at: <https://www.webmd.com/drugs/2/drug-17804/omega-3-oral/details> (Accessed: 13 December 2024).
- Xia, D.-N. *et al.* (2020) 'Omega-3 polyunsaturated fatty acids: a promising approach for the management of oral lichen planus', *Inflammation Research*, 69(10), pp. 989–999. doi: 10.1007/s00011-020-01388-0.
- Yang, Y. and Hu, B. (2014) 'Bio-based chemicals from biorefining: lipid and wax conversion and utilization', in *Advances in Biorefineries*. Elsevier, pp. 693–720. doi: 10.1533/9780857097385.2.693.
- Zhao, Y. *et al.* (2009) 'Effects of *n*-3 Polyunsaturated Fatty Acid Therapy on Plasma Inflammatory Markers and N-Terminal Pro-brain Natriuretic Peptide in Elderly Patients with Chronic Heart Failure', *Journal of International Medical Research*, 37(6), pp. 1831–1841. doi: 10.1177/147323000903700619.